This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies.
Opthea and Unity Biotechnology, which are both developing new drugs for eye dise...
Plus, news about CG Oncology, Opus Genetics and Valneva: Surrozen’s pivot an...
Novo Nordisk is not immune to the trend of seeking obesity assets from China-bas...
Biogen announced on Monday its plans to launch a new headquarters outside Boston...
A small Oakland, CA-based biotech hoping to take on the sprawling landscape of s...
Rounding off a turbulent few years, genetic testing company 23andMe is filing fo...
Augustine Therapeutics has reeled in €77.7 million (about $85 million) to take o...
Hello and welcome back to the new Endpoints Weekly. It was another busy week in ...
The FDA has once again rejected HLB and Jiangsu Hengrui Pharmaceuticals' drug co...
President Donald Trump appears poised to bring back one of the drug pricing poli...
Alnylam will likely face challenges in turning a profit this year, despite execu...
An annual gathering of industry and government officials focused on biomedical c...
Chimerix began attracting deal interest in its experimental brain tumor treatmen...
Novartis’ Fabhalta notched another FDA approval, this time in adults with an ult...
AstraZeneca is again boosting its manufacturing footprint in China, this time ma...